trending Market Intelligence /marketintelligence/en/news-insights/trending/Pw3uFoFSTXEpnltWJJ4e3w2 content esgSubNav
In This List

Sino Biopharmaceutical Q1 profit rises 11.1% YOY

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Sino Biopharmaceutical Q1 profit rises 11.1% YOY

Sino Biopharmaceutical Ltd.'s profit for the first quarter ended March 31 rose 11.1% year-over-year.

Profit attributable to the owners of the parent was about 856.7 million yuan, compared to 771.1 million yuan in the same period a year ago.

EPS attributable to ordinary equity holders of the parent was 6.80 fen, compared to 6.44 fen in the year-ago period.

Revenue for the Hong Kong-based drugmaker rose by 33.4% year over year to 6.21 billion yuan.

As of May 20, US$1 was equivalent to 6.91 yuan.